TMS Co., Ltd. (4891.T)
JPY 140.0
(0.72%)
JPY 140.0
(0.72%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.44 Billion JPY | 3.85% |
| 2022 | -3.58 Billion JPY | -37.98% |
| 2021 | -2.59 Billion JPY | -134.75% |
| 2020 | -1.1 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -3.25 Billion JPY | 5.53% |
| 2024 Q2 | -3 Billion JPY | 7.59% |
| 2023 Q3 | -3.06 Billion JPY | 5.72% |
| 2023 FY | -3.44 Billion JPY | 3.85% |
| 2023 Q2 | -3.24 Billion JPY | 4.98% |
| 2023 Q1 | -3.41 Billion JPY | 4.64% |
| 2023 Q4 | -3.44 Billion JPY | -12.54% |
| 2022 Q2 | -1.99 Billion JPY | 0.0% |
| 2022 Q4 | -3.58 Billion JPY | 6.19% |
| 2022 Q3 | -3.82 Billion JPY | -91.72% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 564.031% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -203.951% |
| GNI Group Ltd. | -17.93 Billion JPY | 80.781% |
| Linical Co., Ltd. | -4.46 Billion JPY | 22.778% |
| Trans Genic Inc. | -221.16 Million JPY | -1458.369% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 21.561% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 28.046% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 340.428% |
| AnGes, Inc. | -3.79 Billion JPY | 9.245% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -719.052% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 113.837% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -591.88% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -639.07% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | -27.364% |
| CanBas Co., Ltd. | -1.88 Billion JPY | -82.535% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -250.93% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | -1.46% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -233.151% |
| Kidswell Bio Corporation | 343.58 Million JPY | 1103.126% |
| PeptiDream Inc. | 3.29 Billion JPY | 204.697% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -254.375% |
| Ribomic Inc. | -2.09 Billion JPY | -64.145% |
| SanBio Company Limited | -3.78 Billion JPY | 9.053% |
| Healios K.K. | -2.19 Billion JPY | -57.38% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -264.777% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | -31.343% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | -143.224% |
| StemRIM | -8.41 Billion JPY | 59.017% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 26.409% |
| FunPep Company Limited | -1.79 Billion JPY | -92.186% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | -61.322% |
| Stella Pharma Corporation | -1.11 Billion JPY | -207.899% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 37.962% |
| Cuorips Inc. | -5.56 Billion JPY | 38.021% |
| K Pharma,Inc. | -3.26 Billion JPY | -5.517% |
| Takara Bio Inc. | -32.2 Billion JPY | 89.297% |
| ReproCELL Incorporated | -2.93 Billion JPY | -17.27% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -421.458% |
| StemCell Institute Inc. | -2.83 Billion JPY | -21.499% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | -66.798% |
| CellSeed Inc. | -2.01 Billion JPY | -71.3% |